

ANNOUNCEMENT

The Board of Directors of Malaysian Genomics Resource Centre Berhad (hereinafter referred to as “MGRC” or “the Company”) and its subsidiaries (“the Group”) hereby announce the following unaudited results for the third quarter ended 31 March 2019.

A PRESENTATION OF RESULTS
I CONDENSED STATEMENT OF PROFIT AND LOSS AND OTHER COMPREHENSIVE INCOME

for the financial period ended	3rd Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	31.3.2019	31.3.2018	31.3.2019	31.3.2018
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Revenue	6,610	6,559	20,709	19,851
Cost of Sales	(4,892)	(4,506)	(14,560)	(12,557)
Gross profit	1,718	2,053	6,149	7,294
Other Income	58	57	341	124
Marketing and distribution	(284)	(531)	(893)	(1,409)
Finance cost	(245)	(157)	(729)	(374)
Administrative expenses	(2,176)	(2,776)	(7,084)	(8,473)
Profit / (loss) before tax	(929)	(1,354)	(2,216)	(2,838)
Income tax expenses	(29)	(103)	(279)	(250)
Profit / (loss), net of tax, representing total comprehensive income	(958)	(1,457)	(2,495)	(3,088)
Profit / (loss) attributable to:				
Owners of the parent	(958)	(1,457)	(2,495)	(3,088)
Net profit / (loss) for the period	(958)	(1,457)	(2,495)	(3,088)
Earnings / (Loss) per share (EPS) attributable to the equity holders of the Company (sen)				
Basic EPS	(0.93)	(1.41)	(2.41)	(2.98)
Diluted EPS	N/A	N/A	N/A	N/A

The unaudited condensed statement of profit and loss and other comprehensive income should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

Notes:-

There is no income/expense in relation to other income including investment income, provision for/write-off of receivables, provision for/write-off of inventories, gain/loss on disposal of quoted or unquoted investments or properties, foreign exchange gain/loss, impairment of assets, gain/loss on derivatives, or exceptional items, except for as disclosed on the cashflow statement.

N/A - Not Applicable

A PRESENTATION OF RESULTS (cont.)
II CONDENSED STATEMENT OF FINANCIAL POSITION

as at	31.3.2019 (RM'000)	30.6.2018 (RM'000)
ASSETS		
NON-CURRENT ASSETS		
Plant and equipment	14,479	13,232
Intangible assets	9,033	9,056
	<u>23,512</u>	<u>22,288</u>
CURRENT ASSETS		
Trade and other receivables	7,444	8,761
Inventories	1,988	2,160
Other current assets	63	6
Tax recoverable	162	248
Cash and bank balances	5,361	7,376
	<u>15,018</u>	<u>18,551</u>
TOTAL ASSETS	<u>38,530</u>	<u>40,839</u>
EQUITY AND LIABILITIES		
EQUITY ATTRIBUTABLE TO OWNERS OF THE PARENT		
Share capital	28,489	28,489
Accumulated losses	(11,214)	(8,719)
TOTAL EQUITY	<u>17,275</u>	<u>19,770</u>
NON-CURRENT LIABILITIES		
Deferred tax liability	676	685
Loans and borrowings	14,121	13,214
	<u>14,797</u>	<u>13,899</u>
CURRENT LIABILITIES		
Trade and other payables	2,490	2,806
Loans and borrowings	3,968	4,364
	<u>6,458</u>	<u>7,170</u>
TOTAL LIABILITIES	<u>21,255</u>	<u>21,069</u>
TOTAL EQUITY AND LIABILITIES	<u>38,530</u>	<u>40,839</u>
Net assets (RM'000)	17,275	24,302
Net assets per share attributable to equity holders of the Company (sen)	16.69	23.48

The unaudited condensed statement of financial position should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)
III CONDENSED STATEMENT OF CHANGES IN EQUITY

	Equity, Total	Non-Distributable			Distributable Retained Earnings / (Accumulated Losses)
		Share Capital	Share Premium	Other reserve	
for the financial year ended 30 June 2018	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 July 2017	24,304	10,351	18,138	(1,682)	(2,503)
Total comprehensive income / (loss)	(4,534)	-	-	-	(4,534)
Transfer to accumulated losses	-	-	-	1,682	(1,682)
Effect of the Companies Act 2016	-	18,138	(18,138)	-	-
Closing balance at 30 June 2018	19,770	28,489	-	-	(8,719)
for the financial period ended 31 March 2019	(RM'000)	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Opening balance at 1 July 2018	19,770	28,489	-	-	(8,719)
Total comprehensive income / (loss)	(2,495)	-	-	-	(2,495)
Closing balance at 31 March 2019	17,275	28,489	-	-	(11,214)

The unaudited condensed statement of changes in equity should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

A PRESENTATION OF RESULTS (cont.)
IV CONDENSED STATEMENT OF CASH FLOWS

for the financial period ended	Year-to-Date	
	Current Year	Previous Year
	31.3.2019 (RM'000)	31.3.2018 (RM'000)
Cash flows from operating activities		
Profit / (loss) before tax	(2,216)	(2,838)
Adjustments for:		
Amortisation of intangible assets	23	481
Depreciation of plant and equipment	834	714
Plant and equipment written off	13	7
Interest income	(134)	(48)
Interest expenses	729	374
Operating profit / (loss) before working capital changes	(751)	(1,310)
(Increase) / decrease in receivables	1,260	1,613
(Increase) / decrease in inventories	172	(395)
(Decrease) / increase in payables	(316)	(2,433)
Cash (used in) / generated from operations	365	(2,525)
Tax refund/(paid)	(202)	(59)
Interest paid	(729)	(374)
Net cash (used in) / generated from operating activities	(566)	(2,958)
Cash flows from investing activities		
Interest received	134	48
Purchase of plant and equipment	(2,094)	(592)
Net cash (used in) / generated from investing activities	(1,960)	(544)
Cash flows from financing activities		
Proceeds from issuance of shares of a subsidiary company	-	7,000
Drawdown of term loan	4,500	6,000
Repayment of loans and borrowings	(3,419)	(1,655)
Net cash generated from / (used in) financing activities	1,081	11,345
Net (decrease) / increase in cash and cash equivalents	(1,445)	7,843
Cash and cash equivalents at beginning of the period	5,923	478
Cash and cash equivalents at end of period	4,478	8,321

The unaudited condensed statement of cash flows should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes that form an integral part of the Interim Financial Statements.

UNAUDITED NOTES TO THE INTERIM FINANCIAL STATEMENTS**B Explanatory Notes Pursuant to MFRS 134****i Basis of Preparation & Changes in Accounting Policies**

These condensed consolidated interim financial statements have been prepared in accordance with MFRS 134 Interim Financial Reporting, and Rule 9.22 and Appendix 9B of the ACE Market Listing Requirements ("Listing Requirements") of Bursa Malaysia Securities Berhad ("Bursa Malaysia").

This report should be read in conjunction with the audited financial statements for the financial year ended 30 June 2018 and the accompanying explanatory notes. The significant accounting policies adopted in preparing these condensed consolidated interim financial statements are consistent with those of the audited financial statements for the financial year ended 30 June 2018.

Details of standards, amendments to published standards and interpretations to existing standards that are applicable to the Group with effect from 1 January 2018 or later are provided in the notes to the audited financial statements of the Group for the financial year ended 30 June 2018.

ii Auditors' Report on Preceding Annual Financial Statements

The audited financial statements for the financial year ended 30 June 2018 were not qualified.

iii Seasonal and Cyclical Factors

The operations of MGRC were not significantly affected by seasonal and cyclical factors.

iv Material and Unusual Items Affecting Assets, Liabilities, Equity, Net Income or Cash Flow

There were no material and unusual items affecting assets, liabilities, equity, net income or cash flows during the financial period.

v Material Changes in Estimates

There were no material changes in the estimates that had effect(s) on the financial period.

vi Debt and Equity Securities

There were no issues, repurchases and repayments of debt and equity securities for the financial period to date.

vii Dividends Paid

There were no dividends paid for the financial period.

B Explanatory Notes Pursuant to MFRS 134 (cont.)**viii Segmental Information**

FRS 8 requires identification of reporting segment on the basis of internal reports that are regularly reviewed by the entity's Managing Director in order to allocate resources to the segment and assess its performance. The management monitors the operating results of the Group as a whole for the purpose of making decisions about resource allocation and performance assessment. Accordingly, the Group has only one reportable segment for the period under review as well as the foreseeable future. Please refer to the financial statements presented in Part A of this announcement.

ix Valuation of Plant and Equipment

There has been no valuation made on any of the Group's plant and equipment during the current financial period under review.

x Subsequent Events

There were no material events subsequent to the end of the current financial period under review that have not been reflected.

xi Changes in the Composition of the Group

There were no changes in the composition of the Group, including business combinations, acquisition or disposal of subsidiaries and long-term investments, restructuring and discontinuing operations for the financial period to date.

xii Contingent Liabilities or Contingent Assets

There was no contingent liability or contingent asset arising since the last audited annual statement of financial position date as at 30 June 2018.

xiii Capital Commitments

There were no material capital commitments for the purchase of property, plant and equipment that were not provided for in the interim financial statements as at the end of the financial period.

B Explanatory Notes Pursuant to MFRS 134 (cont.)
xiv Related Party Transactions

Save as disclosed below, there were no significant related party transactions during the financial period to date:-

Significant Related Party Transactions for the financial period ended		3rd Quarter		Year-to-Date	
		Current Year	Previous Year	Current Year	Previous Year
Related Party	Nature of Transaction	31.3.2019 (RM'000)	31.3.2018 (RM'000)	31.3.2019 (RM'000)	31.3.2018 (RM'000)
Neuramatix, our ultimate holding company	Management fee payable to Neuramatix pursuant to Shared Services Agreement.	183	389	604	1,099
		183	389	604	1,099

xv Cash and Cash Equivalent

as at	Current Year	Previous Year
	31.3.2019 (RM'000)	31.3.2018 (RM'000)
Cash on hand and at banks	1,688	3,421
Deposits with licensed banks	3,673	6,286
Less: Bank overdraft	(883)	(1,386)
	4,478	8,321

xvi Inventories

There was no write-down of inventories during the financial period to date.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements

These condensed consolidated interim financial statements, for the financial period ended 31 March 2019, have been prepared in accordance with Rule 9.22 and Appendix 9B of the Listing Requirements.

i Performance of the Group
Current Year 3rd Quarter versus Previous Year 3rd Quarter

The growth in the pathology revenue was neutralised by a decline in genetic screening services revenue, resulting in the current revenue being consistent with the preceding year's revenue.

Current Year-to-Date versus Previous Year-to-Date

The Group recorded a revenue of RM20.7 million, which represents an increase of RM0.8 million as compared to a revenue of RM19.9 million in the previous year-to-date.

The Group registered a loss before tax of RM2.2 million as compared to a loss before tax of RM2.8 million in the corresponding period of the preceding year. A lower loss was incurred mainly due to higher pathology revenue.

ii Comparison with Preceding Quarter's Results

The comparison of this quarter's results with the preceding quarter is set out below.

	Current Quarter	Preceding Quarter	Variance
for the financial period ended	31.3.2019	31.12.2018	
	(RM'000)	(RM'000)	(RM'000)
Revenue	6,610	6,929	(319)
Profit / (loss) before tax	(929)	(911)	(18)

A lower revenue (RM6.6 million) was achieved in the current period as compared to the preceding quarter's revenue of RM6.9 million, mainly due to lower pathology revenue.

iii Prospects of the Group

With the pathology revenue continuing to drive the business forward, we remain focused on expanding our customer reach in the healthcare sector, differentiating our services and improving operational efficiency.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)
iv Variance from Profit Forecast

The Group did not publish any profit forecast.

v Taxation

Taxation for the financial period ended	3rd Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	31.3.2019	31.3.2018	31.3.2019	31.3.2018
	(RM'000)	(RM'000)	(RM'000)	(RM'000)
Malaysian income tax:				
Current period	29	103	279	250
Prior period	-	-	-	-
Total	29	103	279	250

The above tax has arisen mainly due to the absence of group tax relief.

vi Status of Corporate Proposal

There is no corporate proposal announced but not completed as at the date of this announcement.

vii Loans and Borrowings

The Group's secured loans and borrowing are as follows:-

as at	Current Year	Previous Year
	31.3.2019	31.3.2018
	(RM'000)	(RM'000)
Current		
Hire purchase and finance lease liabilities	-	135
Bank overdrafts	883	1,386
Term loans	3,085	2,973
	3,968	4,494
Non Current		
Term loans	7,121	4,789
Redeemable convertible cumulative preference shares ("RCCPS")	7,000	7,000
	14,121	11,789
Total Loans and borrowings	18,089	16,283

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)

viii Material Litigations

As at the date of this announcement, there is no material litigation against the Group or taken by the Group.

ix Dividends

No dividends were declared during the current financial period under review.

x Trade receivables

The ageing analysis of the Group's trade receivables is as follows:-

	31.3.2019 (RM'000)
Not past due	2,270
Past due	
- less than 3 months	2,990
- 3 to 6 months	768
- over 6 months	1,082
	4,840
Impaired	(180)
	6,930

Receivables that are past due but not impaired

The Group believes that no impairment allowance is necessary in respect of these trade receivables. They are substantially companies with good collection track record and no recent history of default.

C Explanatory Notes Pursuant to Appendix 9B, of the Listing Requirements (cont.)
xi EPS

- a) **Basic EPS** Computed by dividing the profit / (loss), net of tax, attributable to owners of the parent for the financial period by the weighted average of the number of ordinary shares in issue during the period.

Basic EPS for the financial period ended	3rd Quarter		Year-to-Date	
	Current Year	Previous Year	Current Year	Previous Year
	31.3.2019	31.3.2018	31.3.2019	31.3.2018
Profit / (loss), net of tax, attributable to owners of the parent (RM'000)	(958)	(1,457)	(2,495)	(3,088)
Weighted average number of ordinary shares of RM0.10 each in issue ('000)	103,510	103,510	103,510	103,510
Basic EPS (sen)	(0.93)	(1.41)	(2.41)	(2.98)

- b) **Diluted EPS** The Group does not have any convertible shares or convertible financial instruments for the current financial quarter and financial period to date.

xii Disclosure of Realised and Unrealised Profits / (Losses)

as at	31.3.2019 (RM'000)	30.6.2018 (RM'000)
Total accumulated losses:		
Realised	(12,762)	(10,267)
Unrealised	1,491	1,491
Total retained profit/(accumulated losses) of subsidiaries:		
Realised	46	46
Unrealised	11	11
Group accumulated losses	(11,214)	(8,719)

xiii Authorisation for Issue

The interim financial statements were authorised for issue by the Board of Directors of MGRC in accordance with a Resolution of the Directors dated 24 May 2019.